Baker McKenzie Advises on RaySearch Laboratories Share Sale.

Baker McKenzie has advised on the sale of 2 million class B shares in RaySearch Laboratories, a prominent company in the medical technology sector.

The sale, which accounted for 5.8% of the company’s total share capital, was conducted through a book-building procedure and generated 500 million SEK in proceeds.

This transaction underscores RaySearch's ongoing strength in the global medical technology market and provides valuable insight into the company's future trajectory.

The sale of 2 million shares reduces the company’s overall share capital, but it does not alter the control of RaySearch Laboratories.

Following the transaction, the majority of voting rights and significant ownership remain intact with the company's leadership.

Despite selling 5.8% of the shares, the key stakeholders retain enough influence to drive the company's strategies and decision-making processes.

SEB played a pivotal role in the transaction as the Sole Global Coordinator and Bookrunner. Their expertise in structuring and managing the sale ensured the smooth execution of the process.

The sale of 2 million shares in RaySearch Laboratories has been viewed as a positive signal by investors. With the company maintaining strong leadership control and continued global presence in the cancer treatment sector, RaySearch remains an attractive investment opportunity.

This share sale not only provides financial resources but also strengthens the company's market position and ability to innovate in medical technology.

RaySearch Laboratories is a pioneering company focused on advancing cancer treatment through innovative software solutions. Established in 2000 and headquartered in Stockholm, Sweden, the company designs software for radiation therapy that is used worldwide to treat cancer.

RaySearch’s products, such as the RayStation treatment planning system and RayCare oncology information system (OIS), play a crucial role in improving the efficiency and precision of cancer treatments.

Their software solutions support thousands of clinics globally, enabling oncologists to provide more effective and personalized care to cancer patients.

RaySearch is committed to pushing the boundaries of medical science and collaborating with leading cancer centers to bring scientific advancements from the lab to the clinic faster.

The team from Baker McKenzie provided invaluable support, with professionals including Joakim Falkner and Monica Ericson in Stockholm as well as Adam Farlow and Charles Farnsworth in London.

Baker McKenzie is a global law firm, founded in 1949, with over 40 offices worldwide. Known for providing high-quality legal services in areas like corporate law, litigation, and tax, the firm serves businesses, governments, and institutions. With a team of 13,000 professionals, Baker McKenzie is recognized for its innovative solutions, commitment to diversity, and leadership in sustainability.

Baker McKenzie Advises Terra Natural Capital on Panna Afforestation Carbon Credit Deal